FRG Franchise Group, Inc.

Mentions (21)

• Newsglobenewswire.com·1d ago·Neutral

  Harrow Closes Acquisition of TYRVAYA® First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise

  View source ↗
• Newsnewsfilecorp.com·5d ago·Negative

  Stardust Strengthens Franchise Network Through Strategic Territory Optimization Vancouver, British Columbia--(Newsfile Corp. - September 30, 2026) - Stardust Solar Energy Inc. (TSXV: SUN) (OTCQB: SUNXF) (FSE: 6330) ("Stardust Solar" or the "Company"), a North American renewable energy company focused on distributed energy, commercial solar, utility-scale development and long-term renewable energy asset ownership, announces a strategic optimization of its franchise network designed to strengthen

  View source ↗
• Newsglobenewswire.com·7d ago·Positive

  20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md.

  View source ↗
• Newsglobenewswire.com·7d ago·Negative

  SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone

  View source ↗
• Newsseekingalpha.com·11d ago·Neutral

  Manchester United: Ride The Sports Franchise Valuation Wave Up Manchester United plc trades at a significant discount to recent sports franchise valuations, despite improved financials and revenue growth. MANU's market cap of $3.6 billion is roughly half of Forbes' estimated $7.2 billion valuation, highlighting a substantial disconnect. Recent sports franchise transactions and rising TV rights revenues suggest substantial upside for MANU, with scarcity value supporting higher multiples.

  View source ↗
• Newszacks.com·12d ago·Neutral

  Goldman Eyes Palmer Square Buyout to Strengthen Credit & AWM Franchise GS is in talks to acquire Palmer Square, potentially boosting its credit capabilities, AWM franchise and recurring fee revenues.

  View source ↗
• Newszacks.com·14d ago·Neutral

  XYZ's Square Deepens Ideal Nutrition Partnership as Franchise Expands Block's Square expands its Ideal Nutrition partnership as the meal company targets 20 stores by 2026 and explores new markets beyond Florida.

  View source ↗
• Newsglobenewswire.com·18d ago·Neutral

  BetMGM Begins Building “The Traitors” Franchise with the Launch of The Traitors™ Faithful Riches in Alberta and Ontario Exclusive agreement with All3Media International, part of media and entertainment group, Banijay Entertainment, brings the hit television phenomenon to BetMGM Casino and establishes the foundation for a growing portfolio of iGaming content Exclusive agreement with All3Media International, part of media and entertainment group, Banijay Entertainment, brings the hit television ph

  View source ↗
• Newsseekingalpha.com·18d ago·Positive

  Vor Biopharma: A Funded Replication Story With Franchise Potential Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust $514.5M liquidity position. VOR's global Phase 3 trials in myasthenia gravis and Sjögren's are fully enrolled or underway, with topline MG data expected in H1 2027. Competitive pressures from argenx, Amgen, and Novartis require VOR to demonstrate differentiated efficacy, safety, and physician trust for commercial success.

  View source ↗
• Newsprnewswire.com·19d ago·Negative

  Bank7 Corp. to Acquire Century Financial Services Corporation and Expand Southwest Franchise into New Mexico OKLAHOMA CITY, Sept. 17, 2026 /PRNewswire/ -- Bank7 Corp. (NASDAQ: BSVN) (the "Company"), the parent company of Oklahoma City-based Bank7, and Century Financial Services Corporation ("Century"), the Santa Fe, New Mexico-based bank holding company for Century Bank, jointly announce today that they have entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") to which

  View source ↗
• Newsseekingalpha.com·27d ago·Negative

  Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise NERLYNX gives PBYI an established revenue stream that can support alisertib's development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib's biomarker strategy could identify responsive patients, but bear in mind that it's still a speculative asset in Phase 2 trials.

  View source ↗
• Newsglobenewswire.com·28d ago·Neutral

  ZenaTech Plans Franchise Business Model for Drone as a Service Power Washing VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech” or the “Company”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces it is developing a franchise business strategy and plan to bring branded, drone-based power washing servi

  View source ↗
• Newsseekingalpha.com·28d ago·Positive

  Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise Scholar Rock is positioned to launch apitegromab as the first muscle-targeted therapy for SMA, pending FDA approval by September 30, 2026. Manufacturing setbacks were production-based, not due to drug efficacy or safety; the alternate fill-finish facility mitigates approval risk but does not eliminate it. SAPPHIRE trial data support apitegromab's add-on value in SMA, showing statistically significant motor function gains over

  View source ↗
• Newsmarketbeat.com·29d ago·Positive

  Why Franchise Models Are Winning the Restaurant Stock Divide Lower-income consumers have been pulling back on spending. But the impact on quick-service restaurant stocks hasn't been the same.

  View source ↗
• Newsseekingalpha.com·31d ago·Negative

  Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise Avalo Therapeutics (AVTX) is now a well-funded, registrational-stage biotech with validated Phase II data for abdakibart in hidradenitis suppurativa (HS). Abdakibart demonstrated statistically significant HiSCR75 response rates and clean safety, with monthly dosing and efficacy across both biologic-experienced and naive patients. AVTX's $472M cash position secures operations into 2029, reducing near-term dilution risk and enha

  View source ↗
• Newsseekingalpha.com·32d ago·Neutral

  Redwood Trust: Legacy Losses Obscure A Profitable Mortgage Banking Franchise Redwood Trust is rated Buy with a 12-month base case price target of $5.52, reflecting a 35% total return potential. RWT trades at a 33% discount to GAAP book value, as the market over-penalizes legacy asset risks despite strong core mortgage banking performance. Core platforms delivered a 33% annualized return on capital and robust volume growth, but legacy losses continue to drag on consolidated earnings and dividend

  View source ↗
• Newsprnewswire.com·34d ago·Neutral

  Esquire Bank Named a Top Deposit Franchise by S&P Global Market Intelligence for Third Consecutive Year JERICHO, N.Y., Sept. 2, 2026 /PRNewswire/ -- Esquire Financial Holdings, Inc. (NASDAQ: ESQ) ("Esquire"), the parent company for Esquire Bank, National Association ("Esquire Bank" or the "Bank") (collectively "Esquire"), today announced the Bank's inclusion in S&P Global Market Intelligence's annual U.S. Community Bank Deposit Rankings for the third consecutive year.

  View source ↗
• Newsglobenewswire.com·40d ago·Neutral

  First Financial Corporation and First Illinois Corporation Sign Merger Agreement Transaction Strengthens First Financial's Illinois Franchise Through Addition of Hickory Point Bank and Trust Transaction Strengthens First Financial's Illinois Franchise Through Addition of Hickory Point Bank and Trust

  View source ↗
• Newsseekingalpha.com·45d ago·Positive

  Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise Rapport Therapeutics is differentiated by RAP-219's neuroanatomically selective pharmacology and a 22-day half-life, supporting a bullish outlook. RAPP is fully funded through pivotal Phase 3 trials, with $436.1M in cash expected to last into 2H 2029, but it will likely need more capital before commercial launch. RAP-219's long half-life offers a 'forgiveness' advantage for missed doses, but regulatory scrutiny

  View source ↗
• Newsseekingalpha.com·49d ago·Negative

  Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise, leveraging multiple formulations for market segmentation. IMCIVREE's AHO approval and over 400 patient start forms signal robust demand, with a scalable commercial model targeting endocrinologists and neuro-oncologists. RYTM's pipeline—daily, weekly, and oral MC4R agonists—aims to preempt competition and expand reach, while str

  View source ↗
• Newsglobenewswire.com·53d ago·Neutral

  Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulato

  View source ↗